Table 2

Association between MTR genotype, dietary intakes, and risk of adenomatous polyps

WomenMen
DDDGGGP, inter- actiondDDDGGGP, inter- actiond
naORb,c (95% CI)naORb (95% CI)naORb (95% CI)naORb (95% CI)naORb (95% CI)naORb (95% CI)
Unstratified106/2341.0 (reference)60/981.4 (0.9–2.1)11/111.7 (0.7–4.3)201/1431.0 (reference)96/741.0 (0.6–1.4)11/61.6 (0.5–4.6)
Folatee
 High37/841.0 (reference)19/311.6 (0.8–3.4)3/23.1 (0.4–22.1)62/491.0 (reference)32/310.9 (0.4–1.7)2/11.5 (0.1–17.2)
 Medium34/661.2 (0.6–2.2)23/351.3 (0.6–2.7)4/61.2 (0.3–4.8)71/501.1 (0.6–1.9)41/261.1 (0.6–2.3)5/16.4 (0.6–65.0)
 Low35/840.9 (0.4–1.8)18/321.2 (0.5–2.9)4/31.9 (0.3–10.6)68/441.3 (0.7–2.7)23/171.3 (0.6–3.2)4/41.0 (0.2–4.6)
P, trendf1.000.611.000.940.580.610.260.64
Vitamin B12e
 High31/791.0 (reference)15/241.2 (0.5–2.8)3/41.8 (0.3–9.5)63/621.0 (reference)27/251.4 (0.7–2.7)5/22.9 (0.5–17.1)
 Medium31/751.1 (0.6–2.3)19/321.7 (0.7–3.7)2/31.0 (0.1–7.2)76/442.0 (1.1–3.6)46/272.1 (1.1–4.2)2/21.5 (0.2–11.6)
 Low44/801.5 (0.7–3.2)26/422.1 (0.9–4.7)6/43.5 (0.8–15.8)62/372.7 (1.3–5.5)23/221.4 (0.6–3.2)4/24.3 (0.7 (0.7–27.8)
P, trendf0.340.200.310.950.0090.220.430.21
Vitamin B6e
 High33/811.0 (reference)18/301.4 (0.7–3.1)3/31.7 (0.3–10.0)56/531.0 (reference)27/290.9 (0.5–1.9)3/21.2 (0.2–8.5)
 Medium36/721.2 (0.6–2.5)23/351.5 (0.7–3.4)2/31.9 (0.3–14.3)80/441.9 (1.0–3.7)42/251.9 (0.9–4.0)4/32.3 (0.4–12.1)
 Low37/811.1 (0.5–2.5)19/331.6 (0.6–3.9)6/52.0 (0.5–8.5)65/462.1 (1.0–4.7)27/201.9 (0.8–4.8)4/17.4 (0.7–77.5)
P, trendf1.000.761.001.000.040.160.160.78
Methioninee
 High29/651.0 (reference)12/360.6 (0.3–1.5)0/3NA89/691.0 (reference)39/281.2 (0.6–2.2)4/21.7 (0.3–11.1)
 Medium36/790.9 (0.5–1.9)17/281.2 (0.5–2.7)4/41.5 (0.3–7.0)65/381.7 (0.9–3.2)38/251.6 (0.8–3.3)3/22.2 (0.3–14.4)
 Low41/900.7 (0.3–1.6)31/341.5 (0.6–3.7)7/42.1 (0.5–9.5)47/361.7 (0.8–3.7)19/211.2 (0.5–3.0)4/22.8 (0.4–18.2)
P, trendf1.000.270.460.050.380.640.820.63
Alcoholg
 None55/1121.0 (reference)28/620.8 (0.5–1.5)0/4NA66/471.0 (reference)26/220.9 (0.4–1.8)6/31.4 (0.3–6.6)
 Low29/780.9 (0.5–1.5)18/281.6 (0.8–3.3)7/43.7 (0.9–14.8)47/341.0 (0.5–1.9)19/240.6 (0.3–1.3)1/11.4 (0.1–23.6)
 High22/441.0 (0.5–2.0)14/84.0 (1.5–11.1)4/31.9 (0.4–9.3)88/620.9 (0.6–1.6)51/281.3 (0.7–2.5)4/21.7 (0.3–10.1)
P, trendf0.600.620.080.031.000.191.000.55
  • a Number of cases/number of controls.

  • b Adjusted for age, hormone therapy (women only; ever/never), body mass index, pack-years of smoking, regular use of nonsteroidal anti-inflammatory drugs (≥1/week), daily energy intake, dietary fiber, percentage of daily kilocalories from fat, and daily dietary intakes of folate, vitamin B12, vitamin B6, methionine, or alcohol (excluding the nutrient used to stratify).

  • c OR, odds ratio; CI, confidence interval; NA, not calculated.

  • d P for interaction from comparison across genotype groups of OR slopes by dietary component within genotype group.

  • e Tertile cutpoints: folate, 267 and 434 μg; vitamin B12, 5.09 and 9.35 μg; vitamin B6, 1.94 and 3.06 mg; methionine, 1.54 and 2.18 g. Includes intakes from dietary supplements.

  • f P for intragenotype trend in ORs by dietary component from likelihood ratio test of grouped linear vs. continuous models.

  • g Median cut-point for alcohol users, 7 g/day.